A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
Trial details
- Registry ID
- NCT06335173
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173 | Acumen Pharmaceuticals | Phase 2 | Active not recruiting | 2026-10-29Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |